A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
The US-based big pharma MSD has entered the race to be the first to develop…
The Austrian biotech Themis -- specializing in vaccines for infectious and insect-borne diseases -- has…
Vienna-based Themis Biosciences has raised €40M in a Series D round to fund a phase…
Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with…
The market is in sight for the first potential vaccine for the chikungunya virus, as…
Biotech investors regularly jump on new crazes, including the microbiome and CRISPR-Cas9 gene editing. At…
The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead…
UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards…
Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech…
Classical music, the Danube, Schnitzel, and apple strüdel - a typical combination of Vienna. The…
From Switzerland, we depart once again, this time for Vienna. This week, we are visiting…